NCT05546827招募中2 期
Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Rate of Pathologic Response
研究概览
简要总结
The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal melanoma have better outcomes
详细描述
To determine the rate of pathologic response (<50% viable tumor or >50% fibrosis) for non-metastatic sinonasal melanoma patients having surgical resection after receiving neoadjuvant combination immunotherapy followed by radiation therapy.
To determine the rate of pathologic response (<50% viable tumor or >50% fibrosis) for non-metastatic anorectal melanoma patients receiving neoadjuvant intent combination immunotherapy followed by radiation therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For all patients
- •Evidence of mucosal tumor on clinical exam or imaging.
- •No evidence of distant metastasis
- •Patients must be planned for combination immunotherapy (e.g. ipilimumab and nivolumab or nivolumab and relatlimab).
- •ECOG performance status ≤
- •Age ≥18 years because melanoma is extremely rare in patients <18 years of age and RT is considered high risk in this population due to risk of secondary malignancy and potentially growing tissues that may be adversely impacted by RT.
- •RT is a known teratogen. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (refer to MDA Policy CLN 1114) This includes all female patients, between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
- •Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- •History of hysterectomy or bilateral salpingo-oophorectomy.
- •Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- •History of bilateral tubal ligation or another surgical sterilization procedure. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- •Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of RT.
- •Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with their ability to safely receive the study interventions are eligible for this trial.
- •Ability to understand and the willingness to sign a written informed consent document.
- •For Arm 1 patients (sinonasal melanoma)
- •Patients must have histologically or cytologically confirmed melanoma involving the nasal cavity and/or paranasal sinuses.
- •Patients must be evaluated by Head and Neck Surgery to establish surgical status as resectable, borderline resectable or unresectable.
- •Patients must have a baseline skull base MRI unless contraindicated by medical or financial toxicity.
- •For Arm 2 patients (anorectal melanoma)
- •Patients must have histologically or cytologically confirmed melanoma involving the anorectal canal.
- •Patients must be evaluated by the surgical team to establish primary tumor surgical status as: (1) resectable with sphincter sparing approach, (2) resectable with abdominoperineal resection, or (3) unresectable/requiring surgery greater than abdominoperineal resection.
- •Patients must have a baseline rectal MRI unless contraindicated by medical or financial toxicity.
排除标准
- •Previous radiation therapy to the planned target area (sinonasal for Arm 1 and anorectal for Arm 2).
- •Metastatic disease
- •Pregnant women are excluded from this study because RT is a known teratogen.
- •Patients who are less than 18 years of age because melanoma is extremely rare in this population and the treatment agent is a known carcinogen.
研究组 & 干预措施
Sinonasal melanoma: patients with sinonasal melanoma
Experimental
A. Patients with upfront resectable disease
Treatment:
- Immunotherapy
- 20 fraction radiation therapy +/- ongoing immunotherapy
- Surgery
B. Patients whose disease is not resectable at presentation
Treatment:
Immunotherapy with potential to enter resectable disease pathway if tumor becomes resectable or continue treatment as per multidisciplinary team preference if tumor does not become resectable
干预措施: Surgical resection (Procedure)
Anorectal melanoma: patients with anorectal melanoma
Experimental
A. Patients with disease resectable with a sphincter sparing procedure
Treatment:
- Immunotherapy
- 5 fraction radiation therapy
- Surgery
B. Patients with disease not resectable with a sphincter sparing procedure
Treatment:
- Immunotherapy to maximal response
- 5 or 15 fraction radiation (depending on immunotherapy response) +/- ongoing immunotherapy
- Surgery or biopsy
干预措施: Surgical resection (Procedure)
结局指标
主要结局
Rate of Pathologic Response
时间窗: through study completion an average of 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast CancerEstrogen Receptor PositiveHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor PositiveNCT03359954M.D. Anderson Cancer Center25
终止
不适用
Preoperative Proton Radiotherapy for Retroperitoneal SarcomaRetroperitoneal SarcomaNCT00901836University of Florida2
已完成
不适用
Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain MetastasesMalignant Neoplasm BrainNCT02514915Christopher Wilke24
已完成
2 期
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)MSS Locally Advanced Rectal AdenocarcinomaNCT05216653Sir Run Run Shaw Hospital32
招募中
3 期
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal AdenocarcinomaRectal CancerNCT05752136Sir Run Run Shaw Hospital108